The investigative therapy bimekizumab showed significant potential in reducing disease activity and it provided clinically meaningful improvements in ankylosing spondylitis (AS) patients, according to Phase 2b clinical trial data. UCB Pharma recently presented the trial’s findings in a study, “Dual Neutralisation of IL-17a and IL-17F with Bimekizumab in…
Women, compared to men, have a reduced response to certain ankylosing spondylitis treatments, a study has found. The study “Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort” was published in the Journal of Rheumatology. While ankylosing spondylitis has…
A mutation considered to be a risk factor for ankylosing spondylitis has now been questioned in a new large population study. The study, “Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis,…
Social media data has allowed scientists to examine ankylosing spondylitis patients’ knowledge, attitudes, and beliefs regarding biologic therapies. The study, “Patients’ Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights from a Large-Scale Survey of Social Media Platforms,” was published in the journal Arthritis Care &…
Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people without this inflammatory disorder of the same age and sex, a study drawing on real-world medical data reports. Comorbidities seen to have the highest incidence rates among ankylosing spondylitis patients…
The European Medicines Agency has accepted for review Lupin‘s marketing authorization application for YLB113, a biosimilar of etanercept that is marketed by Amgen under the brand name Enbrel. YLB113’s application is for the treatment of ankylosing spondylitis, axial spondyloarthritis, and non-radiographic axial spondyloarthritis, as well as rheumatoid and psoriatic arthritis…
As President Trump signed the recently passed Right to Try legislation into law in a White House ceremony, Jordan McLinn of Indianapolis tried twice to embrace him. The third time, 9-year-old Jordan finally got the hug he wanted — as well as a kiss on the forehead. The video of…
Long-term treatment with Abbvie‘s adalimumab, sold as Humira, led to sustained clinical remission accompanied by better physical abilities in patients with nonradiographic axial spondyloarthritis (nr-axSpA). “Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial”…
Finding treatments and potential cures for rare diseases is crucial, but so is the quality of patients’ lives — a rather nebulous term that means different things to different people. “Recently, there’s been much more of a focus on Quality of Life (QoL) issues, real-world evidence and patient-reported outcomes,” said…
Cimzia (certolizumab pegol) appears to effectively reduce disease activity and manage disease symptoms in patients with axial spondyloarthritis (axSpA) without X-ray evidence of ankylosing spondylitis, according to Phase 3 trial results. The trial also highlights the limitations of current standard-of-care therapies to deliver adequate disease control.
Get regular updates to your inbox.